API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved.
Lead Product(s): Tebipenem Pivoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR994
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2022
Details:
SPR994 (tebipenem pivoxil hydrobromide) is Spero’s novel investigational oral formulation of tebipenem, a carbapenem-class antibiotic in japan it is marketed as Orapenem® since 2009 for pediatric infections limited to pneumonia, otitis media and sinusitis.
Lead Product(s): Tebipenem Pivoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR994
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
Tebipenem HBr is an investigational drug in the United States being developed for the treatment of complicated urinary tract infection, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options.
Lead Product(s): Tebipenem Pivoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR994
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2022
Details:
Oral tebipenem pivoxil hydrobromide, an investigational oral carbapenem antibiotic was noninferior to intravenous ertapenem in the treatment of complicated urinary tract infection and acute pyelonephritis and had a similar safety profile.
Lead Product(s): Tebipenem Pivoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR994
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2022
Details:
The additional funding option is expected to provide support for a clinical trial and related activities for orally administered tebipenem pivoxil’s use in treating pediatric patients with cUTI, including AP.
Lead Product(s): Tebipenem Pivoxil
Therapeutic Area: Infections and Infectious Diseases Product Name: SPR994
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biomedical Advanced Research and Development Authority
Deal Size: $59.7 million Upfront Cash: Undisclosed
Deal Type: Funding January 19, 2022